Our findings underscored the critical role of PCSK9 in regulating E-cadherin degradation and suggest that PCSK9 could serve as a novel therapeutic target for ATC, with implications for expanding the therapeutic landscape for this aggressive cancer. Here, PCSK9 is linked to cancer.